Loading...
Market
Story
GLP-1 Agonists, Including Semaglutide, May Reduce Addiction and Overdose Risks, Study Finds
Oct 17, 2024, 05:32 AM
A new study suggests that GLP-1 agonist medications, such as Ozempic, Wegovy, Mounjaro, Trulicity, and semaglutide, which are commonly used for diabetes management and weight loss, may also help reduce addictive behaviors and prevent opioid overdose. The study, which analyzed 1.3 million health records, found that among people with alcoholism, rates of alcohol intoxication were 50% lower, and among those with opioid addiction, overdose rates were 40% lower. Additionally, these medications were associated with 40% lower rates of hospitalizations for heroin overdose.
View original story
Similar markets
Confirms current findings • 25%
Shows no significant change • 25%
Shows increased risk • 25%
Shows reduced risk but less than current findings • 25%
Opioid overdose reduction • 25%
Alcohol intoxication reduction • 25%
Cardiovascular health improvement • 25%
Other • 25%
Weight Reduction • 25%
Cardiovascular Risk Reduction • 25%
Improved Heart Failure Symptoms • 25%
Other • 25%
Eli Lilly • 25%
Novo Nordisk • 25%
Pfizer • 25%
Other • 25%
Diabetic Macular Edema • 25%
Metabolic Liver Dysfunction • 25%
Addiction Treatment • 25%
Other • 25%
Yes • 50%
No • 50%
Lung Cancer • 25%
Breast Cancer • 25%
Colorectal Cancer • 25%
Other Cancer Type • 25%
Anti-ageing • 25%
Weight loss • 25%
Heart disease reduction • 25%
Other • 25%
No action taken • 25%
Safety label update • 25%
Product recall • 25%
Other regulatory actions • 25%
Increased Coverage • 25%
Decreased Coverage • 25%
No Change • 25%
Other Health Risks Highlighted • 25%
Wegovy • 25%
Zepbound • 25%
Ozempic • 25%
Other • 25%